{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Equine+Anti-thymocyte+globulin&page=2",
    "query": {
      "intervention": "Equine Anti-thymocyte globulin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Equine+Anti-thymocyte+globulin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Equine+Anti-thymocyte+globulin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T20:28:21.194Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04224558",
      "title": "Stem Cell Transplantation in Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Apheresis catheter placement",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "anti-thymocyte globulin (rabbit)",
          "type": "DRUG"
        },
        {
          "name": "lymphocyte immune globulin",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytoxan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "28 Years",
        "sex": "ALL",
        "summary": "13 Years to 28 Years"
      },
      "enrollment_count": 15,
      "start_date": "2019-11-15",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04224558"
    },
    {
      "nct_id": "NCT00305682",
      "title": "Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 295,
      "start_date": "2005-06",
      "completion_date": "2019-12-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00305682"
    },
    {
      "nct_id": "NCT00260689",
      "title": "Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunosuppresion",
        "Thrombocytopenia",
        "Pancytopenia",
        "Neutropenia"
      ],
      "interventions": [
        {
          "name": "Anti-thymocyte globulin (rabbit)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-thymocyte globulin (horse)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2005-11-28",
      "completion_date": "2016-05-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00260689"
    },
    {
      "nct_id": "NCT04304820",
      "title": "Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Horse-Anti-thymocyte-Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "3 Years to 99 Years"
      },
      "enrollment_count": 80,
      "start_date": "2020-05-07",
      "completion_date": "2033-12-18",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04304820"
    },
    {
      "nct_id": "NCT02845596",
      "title": "Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Matched Unrelated Donor Hematopoietic Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "horse anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "rabbit anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "low-dose total body irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Immunosuppressive Therapy (IST)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Michael Pulsipher",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 40,
      "start_date": "2016-08",
      "completion_date": "2023-07-19",
      "has_results": false,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02845596"
    },
    {
      "nct_id": "NCT01623167",
      "title": "Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Cohort 1: hATG, CsA, EPAG Day 14 to Month 6",
          "type": "DRUG"
        },
        {
          "name": "Cohort 2: hATG, CsA, EPAG Day 14 to Month 3",
          "type": "DRUG"
        },
        {
          "name": "Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6",
          "type": "DRUG"
        },
        {
          "name": "Extension Cohort",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "2 Years to 95 Years"
      },
      "enrollment_count": 207,
      "start_date": "2012-07-02",
      "completion_date": "2029-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01623167"
    },
    {
      "nct_id": "NCT03025698",
      "title": "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "hATG",
          "type": "DRUG"
        },
        {
          "name": "CsA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-09-30",
      "completion_date": "2025-01-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03025698"
    },
    {
      "nct_id": "NCT01049854",
      "title": "CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Bone Marrow Failure",
        "Immunodeficiencies",
        "Histiocytosis",
        "Sickle Cell Disease",
        "Beta Thalassemia",
        "Inborn Errors of Metabolism"
      ],
      "interventions": [
        {
          "name": "Full Intensity with TBI",
          "type": "DRUG"
        },
        {
          "name": "Full Intensity",
          "type": "DRUG"
        },
        {
          "name": "Reduced Intensity",
          "type": "DRUG"
        },
        {
          "name": "Reduced Intensity (Fanconi)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-09",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Valhalla, New York",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049854"
    },
    {
      "nct_id": "NCT00801931",
      "title": "Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Neuroblastoma",
        "Immunodeficiencies",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Phenytoin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Horse Antithymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Antithymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-09-06",
      "completion_date": "2009-05-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00801931"
    },
    {
      "nct_id": "NCT02462252",
      "title": "Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia",
        "Hypoplastic Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "BL-8040",
          "type": "DRUG"
        },
        {
          "name": "horse anti-thymocyte globulin (hATG)",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioLineRx, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-10",
      "completion_date": "2020-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-10-05T20:28:21.194Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462252"
    }
  ]
}